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ABSTRACT 22 
Inflammatory bowel diseases (IBD) are a group of common and debilitating chronic intestinal 23 
disorders for which currently-available therapies are often unsatisfactory. The naturally-24 
occurring secondary bile acid, ursodeoxycholic acid (UDCA), has well-established anti-25 
inflammatory and cytoprotective actions and may therefore be effective in treating IBD. 26 
Here, we aimed to investigate regulation of colonic inflammatory responses by UDCA and to 27 
determine the potential impact of bacterial metabolism on its therapeutic actions. The anti-28 
inflammatory efficacy of UDCA, a non-metabolisable analogue, 6-methyl-UDCA (6-29 
MUDCA), and its primary colonic metabolite, lithocholic acid (LCA), were assessed in the 30 
murine DSS model of mucosal injury. The effects of bile acids on cytokine release (TNF-α, 31 
IL-6, Il-1β, IFN-γ) from cultured colonic epithelial cells and mouse colonic tissue in vivo 32 
were investigated. Luminal bile acids were measured by GC-MS. UDCA attenuated release 33 
of proinflammatory cytokines from colonic epithelial cells in vitro and was protective against 34 
the development of colonic inflammation in vivo. In contrast, although 6-MUDCA mimicked 35 
the effects of UDCA on epithelial cytokine release in vitro, it was ineffective in preventing 36 
inflammation in the DSS model. In UDCA-treated mice, LCA became the most common 37 
colonic bile acid. Finally, LCA treatment more potently inhibited epithelial cytokine release 38 
and protected against DSS-induced mucosal inflammation than did UDCA. These studies 39 
identify a new role for the primary metabolite of UDCA, LCA, in preventing colonic 40 
inflammation and suggest that microbial metabolism of UDCA is necessary for the full 41 
expression of its protective actions.  42 
 43 
NEW AND NOTEWORTHY 44 
Based on its cytoprotective and anti-inflammatory actions, the secondary bile acid, 45 
ursodeoxycholic acid (UDCA), has well-established uses in both traditional and Western 46 
medicine. Here, we identify a new role for the primary metabolite of UDCA, lithocholic acid, 47 
as a potent inhibitor of intestinal inflammatory responses and we present data to suggest that 48 
microbial metabolism of UDCA is necessary for the full expression of its protective effects 49 
against colonic inflammation.  50 
 51 
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INTRODUCTION  53 
Inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn’s disease (CD), are 54 
chronic, relapsing inflammatory disorders of the gastrointestinal tract affecting approximately 55 
1% of the adult population of Western countries. While the pathogenesis of inflammation 56 
associated with IBD is still not well-defined, it is widely accepted that a combination of 57 
genetic, environmental, and immunological factors are involved, which drive an 58 
inappropriate mucosal inflammatory response (17). With this in mind, current therapeutic 59 
options employ anti-inflammatory drugs, including glucocorticoids, immunosupressants, 60 
aminosalicylates, and biologics to inhibit mucosal immune responses and production of 61 
proinflammatory cytokines (6). While each of these treatment approaches can be of benefit, 62 
they also have significant drawbacks in terms of the occurrence of side effects, lack of 63 
efficacy, and high cost (42). Thus, more effective, and safer, drugs to treat colitis are much 64 
needed. 65 
Epithelial cells lining the colonic lumen play a key role in IBD pathogenesis (28, 36). One of 66 
the primary physiological roles of the epithelium is to act as an innate barrier against the 67 
uptake of luminal toxins and pathogens. There are several components to this barrier, 68 
including the physical barrier posed by the epithelium itself, along with numerous secreted 69 
factors, such as mucus and cytokines. A hallmark feature of IBD is dysregulation of epithelial 70 
barrier function with associated increases in permeability and induction of cytokine release 71 
(2, 30). Many endogenous and exogenous components of the luminal contents have been 72 
shown to have the capacity to promote epithelial cytokine release, including bacterial toxins 73 
and cell wall components, viral RNA, and bile acids, all of which are altered in the setting of 74 
gut inflammation (8, 26, 27). Thus, given its central role in the development of colitis, the 75 
epithelium is currently receiving a great deal of interest as a target for the development of 76 
new treatments (28, 42).  77 
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Ursodeoxycholic acid (UDCA) is a naturally-occurring secondary bile acid, produced in the 78 
colon by bacterial metabolism of the primary bile acid chenodeoxycholic acid (CDCA). 79 
UDCA is considered to be unique among bile acids as it has long been recognized to have 80 
broad-ranging protective actions. Indeed, UDCA is often referred to as the “therapeutic” bile 81 
acid as it has been used for centuries in Traditional Chinese Medicine, as a component of 82 
bear bile, to treat diverse maladies, such as failing eyesight, intestinal malaise, impotency, 83 
and fever (10). More recently, in Western medicine, UDCA has been used to treat liver 84 
inflammation and cholestasis (24, 47), and currently it is also under investigation for a 85 
number of conditions, including neurological, ocular, cardiovascular, and metabolic disorders 86 
(45). Importantly, unless it is used at high doses (9), UDCA is a safe drug with few side 87 
effects. While its mechanisms of action are not well-defined, it is believed that the therapeutic 88 
properties of UDCA are largely due to its anti-inflammatory and cytoprotective actions (5, 89 
45). The biological actions of UDCA have been mostly studied in the liver, where it has been 90 
shown to exert immunomodulatory and anti-apoptotic actions, and to prevent cytokine release 91 
(7, 33, 34, 37). In the current study, we hypothesised that by virtue of its anti-inflammatory 92 
and cytoprotective properties, UDCA is a represents a promising target for development of 93 
new treatments for diseases associated with intestinal inflammation. However, when 94 
considering UDCA as a potential therapeutic for intestinal disease, it is also important to 95 
consider that in vivo, it is extensively metabolised by the colonic microbiome and the effects 96 
that this has on its therapeutic activity are not known. Thus, in the current study we used in 97 
vitro and in vivo models to investigate the anti-inflammatory effects of UDCA in the colon 98 
and the potential consequences of bacterial metabolism on its therapeutic actions. 99 
 100 
  101 
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MATERIALS AND METHODS: 102 
Ethical Approval: All experiments carried out on mice conformed to the Animal Research: 103 
Reporting of In Vivo Experiments (ARRIVE) guidelines and were approved by the RCSI 104 
Research Ethics Committee (REC739) and by the Irish Department of Health and Children 105 
(B100/4159).  106 
Animal Studies: All experiments carried out on mice conformed to the Animal Research: 107 
Reporting of In Vivo Experiments (ARRIVE) guidelines and were approved by the RCSI 108 
Research Ethics Committee (REC739) and by the Irish Department of Health and Children 109 
(B100/4159). Male C57Bl/6 mice were used between 10 – 12 weeks of age. Colitis was 110 
induced in mice by addition of 2.5 % DSS (MP Biomedicals, Solon, OH) to their drinking 111 
water for 5 days. Disease activity index (DAI) was used as a measure of disease progression 112 
and was calculated by the addition of scores designated to body weight, faecal blood and 113 
stool consistency/diarrhoea, as previously described (39). Starting 24 hrs before 114 
administration of DSS, and once daily thereafter, animals received by intraperitoneal 115 
injection, either endotoxin-free PBS as vehicle control, Na+-UDCA (30 or 100 mg/kg),  Na+-116 
6-MUDCA or Na+-LCA (30 mg/kg) dissolved in PBS. Mice were sacrificed on day 6, the 117 
length of their colons was recorded, caecal contents were kept for analysis, and colonic tissue 118 
was processed for H&E staining, or for analysis of cytokine expression. For histological 119 
scoring, approximately 1 cm sections of colonic tissue were fixed in 10% paraformaldehyde 120 
(pH 7.4; PBS buffered) and embedded in paraffin. Sections (4 μm) were cut and stained with 121 
H&E. All sections were examined in a blinded fashion independently by 2 observers and 122 
histologic scoring was carried out, as previously described (39). Blood was collected at time 123 
of sacrifice by cardiac puncture. Serum was obtained by centrifugation (2,000 x g for 10 124 
minutes, 4oC), aliquoted, and stored at -80oC until use. Serum creatinine and ALT were 125 
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measured using the RXL Dimension Autoanalyser platform (Siemens Healthcare 126 
Diagnostics, Munich, Germany). 127 
Cytokine Measurements: T84 or HT29Cl19A cells were cultured on 96-well plates until they 128 
reached approximately 80% confluence. Cells were serum-starved for 1hr prior to stimulation 129 
with polyinosinic:polycytidylic acid (poly I:C) (25 μg/ml) or TNF-α (10 ng/ml) in the 130 
presence or absence of UDCA or LCA (24 hr, 37°C). Mouse colons were homogenised in 131 
liquid N2 on dry ice, re-suspended by vortexing in lysis buffer (1% Nonidet P-40, 150 m 132 
NaCl, 50 mmol/L Tris Base, 1 x Complete mini EDTA free protease inhibitor tablet, 0.1 133 
mg/1mL PMSF, 1 mmol/L Na3VO4) in a m/v ratio of 1:5, lysed (45 minutes on ice), 134 
sonicated (3 x 10s pulses), centrifuged (15,294 x g, 20 mins, 4°C) and supernatants were 135 
retained for analysis. For measurements of TNF-α, IL-1β, IL-6, IFN-γ, IL-12p70, and GM-136 
CSF cell culture supernatants or colonic lysates were then added to a pre-coated V-Plex 137 
Multi-array and Multi-sport Human Cytokine Assay plates (Catalogue #: K15007B-1) and 138 
assayed as per the manufacturer’s protocol (Meso Scale Diagnostics; Rockville, MD). 139 
Measurements of IL-8 release from T84 cells were carried out by ELISA (Beckton Dickinson, 140 
San Diego, CA). 141 
Caecal bile acid analysis: Caecal contents were collected from treated and control animals 142 
and stored in isopropanol at −20°C. Caecal bile acid levels were measured by HPLC-ES-143 
MS/MS, as previously described (38). 144 
Acid Phosphatase Assay: T84 cells grown to confluency on 96-well plates were serum-145 
starved for 1hr prior to treatment with LCA.  Cells were then washed in warm PBS, incubated 146 
in sodium acetate buffer (0.1M C2H3NaO2, pH 5.5, 0.1% Triton x-100) protected from light 147 
at 37°C for 30 mins, following which absorbance was recorded at 404 nm. 148 
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Statistical Analysis:  Results are expressed as mean ± SEM for a series of n experiments.  149 
Data were assumed to be normally distributed and statistical analyses were carried out using 150 
GraphPad Instat software (GraphPad, San Diego, CA). Paired t-test were used for 151 
comparisons of paired treatments between 2 groups, unpaired t-tests for comparisons of 152 
unpaired treatments between 2 groups, and one way ANOVA using Tukey multiple 153 
comparisons test for treatments of 3 groups or more.  p values ≤ 0.05 were considered to be 154 
significant. 155 
 156 
RESULTS 157 
UDCA inhibits pro-inflammatory cytokine release from colonic epithelial cells: First, we 158 
investigated the effects of UDCA on release of pro-inflammatory cytokines from T84 colonic 159 
epithelial cells.  For these studies, we used the TLR-3 agonist, poly I:C (25 μg/ml), as a 160 
stimulus and cytokines released into the bathing media were analysed using validated 161 
multiplex arrays. We found that Poly I:C induced secretion of TNF-α from T84 cells and that 162 
UDCA significantly attenuated this response in a concentration-dependent manner, with a 163 
maximal effect occurring at 200 μM (Figure 1A). UDCA (200 μM) also attenuated Poly I:C-164 
induced secretion of IL-1β, and IL-6 (Figures 1B and C).  In contrast, UDCA did not alter 165 
Poly I:C-stimulated IFN-γ release (Figure 1D), or that of IL-12p70 and GM-CSF (data not 166 
shown).  167 
UDCA exerts protective effects in the DSS model of mucosal inflammation: Next, we 168 
went on to examine the effects of UDCA in the DSS mouse model of mucosal inflammation. 169 
The DSS model is considered to be a particularly good model for studying mucosal 170 
inflammation occurring as a consequence of disrupted epithelial barrier function (31, 48). 171 
Inclusion of 2.5% DSS in the drinking water of C57/BL6 mice led to a reduction in body 172 
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weight and increased DAI over the 5 day experimental period. Both effects were significantly 173 
attenuated by daily treatment with UDCA (30 mg/kg) (Figures 2A-B). UDCA at a higher 174 
dose of 100 mg/kg (Day 5 DAI = 5.8 ± 0.5) did not confer additional protection when 175 
compared to its effects at 30 mg/kg (Day 5 DAI = 6.8 ± 0.9; n = 6). Mice treated with DSS 176 
also had significantly shorter colons (60.8 ± 2.1 mm) and lack of faecal pellet formation 177 
compared to controls (87.2 ± 2.1 mm, n = 6 – 12, p ≤ 0.001), whereas treatment with UDCA 178 
(30 mg/kg) prevented shortening of the colon (69.0 ± 1.5 mm, n = 6 – 12, p ≤ 0.05) and 179 
restored faecal pellet formation (Figures 2 C). Histological studies revealed that UDCA 180 
reduced inflammatory cell infiltration and prevented epithelial damage, leading to a reduction 181 
in overall inflammation score (Figure 2D-E). As shown in Figure 3, UDCA also tended to 182 
reduce levels of TNF-α, IL-1β, and IL-6, although none of these effects achieved statistical 183 
significance. Similar to its effects in T84 cells, UDCA did not attenuate IFN-γ levels and, in 184 
fact, tended to enhance DSS-induced release of this cytokine.  185 
6-MUDCA is not protective against DSS-induced colonic inflammation: In humans, 186 
UDCA is known to be metabolised to LCA in the colon and GC-MS analysis of the caecal 187 
contents revealed that this is also the case in mice (Figure 4A). Thus, we hypothesised that 188 
bacterial metabolism of UDCA likely limits its therapeutic effects. To test this, we employed 189 
a 6-methylated derivative of UDCA, 6α-methyl-UDCA (6-MUDCA), which cannot be 190 
metabolised by bacteria to LCA or other metabolites (32). We have previously shown 6-191 
MUDCA not to be metabolised to LCA in mice, but to retain the biological activity of UDCA 192 
in vitro (16). Here, we confirmed that 6-MUDCA also retains the activity of UDCA in 193 
preventing poly I:C-induced TNF-α release from T84 cell monolayers (Figure 4B). 6-194 
MUDCA was also active in HT29Cl19A cells, reducing Poly I:C (25 µg/ml)-induced TNF-α 195 
release from 378 ± 108 pg/ml in controls to 236 ± 59 pg/ml (n = 3; p ≤ 0.01), indicating its 196 
effects are not cell line-specific.  However, despite its capacity to prevent colonic epithelial 197 
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cytokine secretion in vitro, in contrast to UDCA, 6-MUDCA was not protective against DSS-198 
induced mucosal inflammation in vivo, as assessed by DAI measurements (Figure 4C). 199 
Similarly, 6-MUDCA did not prevent weight loss or colon shortening in response to DSS 200 
treatment. Body weight was reduced to 94.8 ± 0.5% of controls in response to DSS-treatment, 201 
compared to 90.0 ± 2.1% in 6-MUDCA-treated mice, whereas colon length in DSS-treated 202 
mice was 59.3 ± 1.5 mm compared to 57.7 ± 1.5 mm in those co-treated with 6-MUDCA. 203 
This lack of efficacy of 6-MUDCA was contrary to our original hypothesis, and suggest that 204 
bacterial metabolism of UDCA is necessary for it to exert its protective effects in vivo. 205 
LCA inhibits pro-inflammatory cytokine release from colonic epithelial cells: Since 206 
metabolism of UDCA appears to be required for it to exert protective actions, we went on to 207 
investigate the effects of its major colonic metabolite, LCA, in regulating colonic 208 
inflammatory responses. First, we examined LCA effects on cytokine release from colonic 209 
epithelial cells in vitro. T84 cells were treated with poly I:C, either in the absence or presence 210 
of LCA (0.1 – 10 μM) and TNF-α secretion into the bathing medium was measured. 211 
Interestingly, we found that LCA treatment was considerably more effective than UDCA, 212 
practically abolishing poly I:C-induced TNF-α release (Figure 5A and c.f. Figure 1A). 213 
Furthermore, the effects of LCA were not specific to TLR3 activation by Poly I:C, since the 214 
bile acid also inhibited IL-8 cytokine secretion in response to another pro-inflammatory 215 
stimulus, TNF-α (Figure 5B). Use of the acid phosphatase activity assay, as a direct index of 216 
the number of cells present, revealed only a slight reduction associated with this effect of the 217 
bile acid (Figure 5C). To further assess potential LCA toxicity on colonic epithelial cells, we 218 
examined its effects on transepithelial resistance (TER), a sensitive index of epithelial 219 
monolayer integrity. After 24 hrs treatment, the TER of LCA (10 µM)-treated T84 cells was 220 
94 ± 2.6% (n = 5) of that in controls, indicating that, at concentrations which abolish cytokine 221 
secretion, LCA does not alter monolayer integrity. 222 
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LCA is protective against DSS-induced colonic inflammation and cytokine release: We 223 
next examined the effects of LCA on DSS-induced colonic inflammation in vivo. Daily 224 
treatment with LCA (30 mg/kg; IP) significantly increased caecal LCA levels from 6.1 ± 0.5 225 
to 15.7 ± 3.1 μM in controls and from 2.0 ± 0.3 to 11.5 ± 2.1 μM in DSS-treated mice (n = 5, 226 
p ≤ 0.05). We noted that treatment with LCA alone induced a significant loss of body weight 227 
by day 5 to 89.3 ± 1.0 % of that before LCA treatment (Figure 6A), consequently causing a 228 
slight, non-significant, increase in DAI (Figure 6B). Interestingly, LCA almost completely 229 
prevented the onset of inflammation, as measured by DAI, which in DSS-treated animals was 230 
11.2 ± 0.9 compared to 5.2 ± 0.6 in LCA-treated mice (n = 5, p ≤ 0.001) (Figure 6B).  LCA 231 
alone caused a slight shortening of the colon but prevented that caused by DSS treatment and 232 
restored the appearance of normal stool pellets (Figures 6C). Furthermore, LCA completely 233 
reversed DSS-induced changes in mucosal histology and increases in inflammation score 234 
(Figure 6D-E). An analysis of the effects of LCA on levels of proinflammatory cytokines 235 
revealed that it was even more effective than UDCA in reducing mucosal levels of TNF-α, 236 
IL-6, and IL-1β in DSS-treated mice (Figure 7). Interestingly, in contrast to UDCA, 237 
administration of LCA also inhibited Poly I:C-induced increases in IFN-γ. Mice treated with 238 
LCA actions were not associated with any apparent signs of systemic toxicity, as determined 239 
by measurements of serum creatinine and ALT. Serum creatinine levels were 35.7 ± 1.2, 29.0 240 
± 2.0 and 31.3 ± 1.8 mM/L in control, DSS, and DSS + LCA-treated mice, respectively (n = 241 
3), while ALT levels  were determined to be < 6 U/L in all treatment groups.  242 
 243 
  244 
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DISCUSSION 245 
By virtue of its potent anti-inflammatory and cytoprotective properties, UDCA is recognised 246 
as a drug with great therapeutic potential (45), and our current studies add to a growing body 247 
of evidence that suggest it may also be useful in treatment of intestinal inflammation. Our 248 
studies also show that the protective effects of UDCA are likely to be due, at least in part, to 249 
inhibition of epithelial cytokine production and point to an important role for bacterial 250 
metabolism in determining its efficacy in vivo.   251 
An early step in intestinal inflammatory responses is the production of cytokines from the 252 
epithelium in response to various luminal factors, such as bacteria and their toxins and 253 
metabolites. Viruses are also present and their importance in IBD pathogenesis has recently 254 
been highlighted (27). Viruses promote cytokine secretion through the release of double-255 
stranded RNA which activates epithelial Toll-like receptors (TLRs), in particular TLR3 (1, 256 
11), and here we found that such responses are inhibited by UDCA treatment. These findings 257 
are particularly interesting in the context of recently published data, where the effects of the 258 
conjugated derivative of UDCA, tauro-UDCA (TUDCA) were investigated in the DSS model 259 
(21). Although, significantly higher doses were required, similar to UDCA, TUDCA 260 
prevented the development of mucosal inflammation, an effect that was closely associated 261 
with inhibition of epithelial apoptosis. Also similar to our own studies, UDCA was found to 262 
prevent colonic inflammation in TNBS-treated rats, a model of intestinal inflammation 263 
distinct to that used in the current studies (25). Thus, UDCA has the capacity to prevent both 264 
the elevated cytokine levels and increased epithelial permeability associated with intestinal 265 
inflammation, suggesting it should be of therapeutic benefit in patients with IBD.   266 
However, when considering the use of UDCA for treatment of colonic disease, it important to 267 
consider the potential impact of the colonic microbiota on its actions. Bile acids entering the 268 
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colon undergo rapid metabolism by resident bacteria by deconjugation, dehydroxylation and 269 
epimerisation and therefore, the fate of UDCA in the colon is determined by the relative 270 
expression of bacterial hydrolases, dehydratases, and epimerases (20, 22). How UDCA 271 
administration changes the makeup of the colonic bile acid pool is not well-defined but 272 
studies in humans show that after UDCA treatment, LCA becomes the most prominent 273 
colonic bile acid (44). This is supported by our current studies which showed extensive 274 
metabolism of UDCA to LCA in the cecum of normal mice. It was also interesting to note 275 
that in DSS-treated mice, despite the fact that it prevented inflammation, levels of UDCA in 276 
the colon did not increase appreciably after administration of the bile acid, while those of 277 
LCA increased approximately 4-fold. Also notable in these studies was the effect of DSS 278 
treatment in reducing cecal levels of UDCA and LCA. These data are in line with a previous 279 
study demonstrating fecal LCA levels to be decreased in DSS-treated mice (3), and a more 280 
recent study demonstrating that levels of both UDCA and LCA are reduced in this model of 281 
colonic inflammation. Furthermore, such changes were found to be associated with 282 
significant alterations in the colonic microbiota and were partially restored by UDCA 283 
treatment (43). Further studies to more precisely determine how changes in the microbiota 284 
and related alterations in the colonic bile acid signature contribute to the onset of 285 
inflammation and how UDCA administration influences such processes warrants further 286 
investigation. 287 
LCA is the most lipophillic of the secondary colonic bile acids and is classically considered 288 
to be relatively toxic, particularly in the liver (15). Increased levels of hepatic LCA, which 289 
occur in conditions of cholestasis, are thought to contribute to liver damage though induction 290 
of apoptotic cell death. Indeed, several studies have demonstrated that supraphysiological 291 
levels of LCA, cause oxidative stress, DNA damage and induce apoptosis in both hepatocytes 292 
and colonic epithelial cells (4). Thus, since UDCA is normally metabolised to LCA in the 293 
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colon, we hypothesised that this may be a factor that limits its therapeutic actions. To test this 294 
hypothesis we used 6-MUDCA, a non-metabolizable derivative of UDCA, which we have 295 
previously shown to not be metabolised to LCA either in mouse colon or by the human fecal 296 
microbiota (16, 32). To our surprise we found that, even though, similar to UDCA, it inhibits 297 
epithelial cytokine production in vitro, 6-MUDCA did not confer protection in the DSS 298 
model. These findings were contrary to our hypothesis and suggest that, rather than limiting 299 
its therapeutic actions, bacterial metabolism of UDCA is actually required for it to fully exert 300 
its protective effects. 301 
While most previous studies have focussed on the cytotoxic actions of LCA at high 302 
concentrations, few have investigated whether it might also have more physiological roles to 303 
play. Interestingly, one recent study showed that administration of LCA to mice by enema 304 
can prevent colonic epithelial apoptosis, and therefore presumably promote barrier function 305 
(18). In the current studies, we found that even at concentrations as low as 10 µM, which 306 
approximates its normal physiological range in the colon (13), LCA was even more effective 307 
than UDCA in preventing TNF-α release from colonic epithelial cells in vitro. Even more 308 
remarkably, we found that when administered to mice, LCA was also more effective than 309 
UDCA in preventing DSS-induced inflammation. Further analysis showed that cytokine 310 
release from mucosal tissues was practically abolished in LCA-treated mice, compared to the 311 
partial inhibition observed with UDCA treatment. Notably, while UDCA tended to increase 312 
mucosal levels of IFN-γ in DSS-treated mice, LCA inhibited accumulation of this cytokine.  313 
While we were concerned that the effects of LCA might be due to toxicity, this does not 314 
appear to be the case, as indicated by a lack of effect of the bile acid on TER across epithelial 315 
monolayers and only a modest effect on cell number at concentrations that abolish cytokine 316 
release. Furthermore, no overt toxicity was apparent in histological sections of colonic tissue 317 
from LCA-treated mice, nor were serum levels of creatinine or ALT altered by the bile acid. 318 
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However, it was notable that LCA treatment significantly reduced body weight over the 319 
course of the experiment. Given the lack of apparent local or systemic toxicity, we speculate 320 
that this could either be due to reduced food intake in the LCA-treated mice, or alternatively, 321 
might reflect effects of the bile acid on energy expenditure and fat metabolism. This latter 322 
hypothesis seems is possible since previous studies have shown that bile acids prevent weight 323 
gain in mice on a high fat diet (46), and that this effect is mimicked by the TGR5-selective 324 
agonist, INT-777 (19, 41).  TGR5 is now accepted to play an important role in regulating 325 
metabolism (23), suggesting that LCA, as a natural agonist of the receptor, could be an 326 
endogenous regulator of metabolism, energy expenditure and body weight. Separating such 327 
dual actions on metabolism and inflammation is an important issue to consider when 328 
developing bile acids, or synthetic agonists, as therapeutics for IBD. However, it is notable 329 
that studies by Harach and co-workers indicate that agonists of TGR5 influence metabolism 330 
only when they are present in the systemic circulation, suggesting that colonic or rectal 331 
delivery of such drugs may be the optimal approach for their use in treating colitis, while 332 
minimising effects on weight (14).  333 
Although UDCA shows excellent potential for therapeutic development in treating intestinal 334 
inflammation, there is still much work to be done to elucidate mechanisms underlying its 335 
effects. While our current studies suggest that its metabolism to LCA may be important, it is 336 
also possible that other metabolites may be involved. For example, 7-keto-LCA, formed by 337 
the action of 7β-hydroxysteroid dehydrogenase, is the major metabolic intermediate of 338 
UDCA and LCA and its actions on colonic epithelial physiology are not yet known. 339 
Similarly, how sulfation of UDCA and LCA alter their physiological/pathophysiological 340 
actions remains to be determined. It is also important to develop our understanding of the role 341 
of the microbiota in modulating bile acid actions on colonic epithelial barrier function. This is 342 
particularly important in the setting of inflammation, where the microbiome is known to be 343 
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significantly altered (8). Such alterations would undoubtedly influence metabolism of UDCA, 344 
the generation of its metabolites, and consequently, its therapeutic actions. Finally, the 345 
molecular pathways underlying the anti-inflammatory effects of UDCA and its metabolites 346 
and their differential effects on epithelial cytokine secretion remain to be fully elucidated. In 347 
this regard, several bile acid receptors are expressed in the colonic epithelium, including 348 
TGR5 and the nuclear receptors, farnesoid x receptor, pregnane x receptor, and vitamin D 349 
receptor, each of which has been shown to protect against colonic inflammation in animal 350 
models (12, 29, 35, 40). Although structurally similar, UDCA and LCA have very different 351 
actions at these receptors, likely underlying different responses to the bile acids. Future work 352 
should aim to elucidate how expression of these receptors is altered in conditions of colonic 353 
inflammation and how this impacts the effects of UDCA and its metabolites on epithelial 354 
function.  355 
In conclusion, our studies support the hypothesis that UDCA may be useful as a new therapy 356 
for alleviating or preventing chronic intestinal inflammation but that bacterial metabolism of 357 
the bile acid is necessary for its full therapeutic benefit to be apparent. We also demonstrate a 358 
new anti-inflammatory role for the primary UDCA metabolite, LCA, in the colon, which 359 
suggests it may be an important mediator of UDCA effects. Further studies are necessary to 360 
more completely understand how the colonic microbiome and bile acids interact in order to 361 
regulate epithelial barrier function in health and disease.  362 
  363 
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FIGURE LEGENDS 364 
Figure 1. UDCA attenuates proinflammatory cytokine release from colonic epithelial 365 
cells. T84 cells grown on 96-well plates were serum-starved for 1hr prior to stimulation with 366 
poly I:C (25 μg/ml) in the presence or absence of UDCA. After 24 hrs, supernatants were 367 
collected and analysed for A) TNF-α (n = 6), B) IL-6, C) IL-1β, and D) IFN-γ (n = 4). *p < 368 
0.05, **p < 0.01, ***p < 0.001 compared to control cells; #p < 005,  ##p < 0.01 compared to 369 
cells treated with poly I:C alone. 370 
Figure 2. UDCA exerts protective effects in the DSS model of mucosal inflammation. 371 
Starting 24 hrs prior to administration of DSS (2.5% in the drinking water), and daily 372 
thereafter, separate groups of male C57BL6 mice received either endotoxin-free PBS or Na+-373 
UDCA (30 mg/kg or 100 mg/kg, dissolved in PBS) by IP injection.  A) Disease activity index 374 
(DAI) and B) body weight were assessed daily to monitor disease progression (n = 6 - 12 375 
throughout). C) Mice were sacrificed on day 6 and their colons were removed and measured. 376 
D) Sections of colon from control, DSS-treated, UDCA-treated, and DSS+UDCA-treated 377 
C57BL6 mice were taken and processed for H&E staining. Sections were visualised by light 378 
microscopy under 10x magnification. E) Inflammation score was assessed as described in 379 
Materials and Methods. *** p < 0.001 compared to controls (no DSS treatment); # p < 0.05,  380 
## p < 0.01, ## p < 0.001  compared to DSS-treated mice. 381 
Figure 3. UDCA modulates expression of pro-inflammatory cytokines in the DSS model 382 
of mucosal inflammation. Sections of colon from control, DSS-treated, UDCA-treated, and 383 
DSS+UDCA-treated C57BL6 mice were homogenised in lysis buffer and were analysed by 384 
MSD assay for A) TNF-α, B) IL-6, C) IL-1β, and D) IFN-γ. n = 6 – 12; **p < 0.01, ***p < 385 
0.001 compared to controls (no DSS treatment). n.s. = not significant. 386 
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Figure 4. A metabolically stable analogue of UDCA, 6-MUDCA, is not protective 387 
against DSS-induced colonic inflammation: A) Caecal contents were collected from treated 388 
and control mice and bile acid levels were measured by HPLC-ES-MS/MS. B) T84 cells were 389 
stimulated with poly I:C (25 μg/ml) in the presence or absence of UDCA or 6-methyl-UDCA 390 
(200 μM; bilateral). After 24 hrs, supernatants were collected and analysed for TNF-α. Data 391 
are expressed as fold change with respect to cells treated with poly I:C alone (n = 5; ***p < 392 
0.001). C) Starting 24hrs prior to administration of DSS (2.5% in the drinking water), and 393 
daily thereafter, separate groups of male C57BL6 mice received either endotoxin-free PBS or 394 
Na+-6-MUDCA (30 mg/kg) by IP injection. DAI was assessed daily to monitor disease 395 
progression. (n = 3 - 9).  396 
Figure 5. LCA exerts anti-inflammatory effects in vitro. A) T84 cells were stimulated with 397 
poly I:C (25 μg/ml) in the presence or absence of LCA (1 nM - 10 μM). After 24 hrs, 398 
supernatants were collected and analysed for TNF-α. Data are expressed as fold change with 399 
respect to cells treated with poly I:C alone (n = 7; ***p < 0.001). B) T84 cells were treated 400 
with TNF-α (10 ng/ml) and LCA (10 µM) alone or in combination. After 24 hrs apical media 401 
were collected and analysed for IL-8 levels bu ELISA. Data are expressed as fold change 402 
with respect to cells treated with TNF-α alone (n = 4; ***p < 0.001). C) T84 cells grown on 403 
96 well plates were serum starved for 1 hr prior to treatment with LCA (1 nM to 1 mM) for 404 
24 hrs (n = 4), after which acid phosphatase activity was measured (**p < 0.01, ***p < 0.001 405 
compared to untreated cells).   406 
Figure 6. LCA exerts protective effects in the DSS model of mucosal inflammation. 407 
Starting 24 hrs prior to administration of DSS in the drinking water, and daily thereafter, 408 
separate groups of male C57BL6 mice received either endotoxin-free PBS or Na+-LCA (30 409 
mg/kg) by IP injection.  A) Body weight and B) disease activity index (DAI) were assessed 410 
18 
 
daily to monitor disease progression (n = 5). C) Mice were sacrificed on day 6 and their 411 
colons were removed and measured (image is representative of n = 5). D) Sections of colon 412 
from control, DSS-treated, LCA (30 mg/kg)-treated, and DSS+LCA-treated C57BL6 mice 413 
were taken and processed for H&E staining. Sections were visualised by light microscopy 414 
under 10x magnification. E) Inflammation score was assessed as described in Materials and 415 
Methods (n = 3 – 5). *p < 0.05, **p < 0.01, ***p < 0.001 compared to controls (no DSS 416 
treatment); #p < 0.05,  ##p < 0.01, compared to DSS-treated mice 417 
Figure 7. LCA modulates the expression of pro-inflammatory cytokines in murine 418 
colon. Sections of colon from control, DSS-treated, LCA (30 mg/kg)-treated, and DSS+LCA-419 
treated C57BL6 mice were homogenised in lysis buffer and were analysed for A) TNF-α, B) 420 
IL-6, C) IL-1β, and D) IFN-γ. n = 3 – 10; **p < 0.01, ***p < 0.001 compared to controls (no 421 
DSS treatment). 422 
 423 
  424 
19 
 
REFERENCES 425 
1. Alexopoulou L, Holt AC, Medzhitov R, and Flavell RA. Recognition of double-426 
stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738, 427 
2001. 428 
 429 
2. Antoni L, Nuding S, Wehkamp J, and Stange EF. Intestinal barrier in 430 
inflammatory bowel disease. World J Gastroenterol 20: 1165-1179, 2014. 431 
 432 
3. Araki Y, Andoh A, Tsujikawa T, Fujiyama Y, and Bamba T. Alterations in 433 
intestinal microflora, faecal bile acids and short chain fatty acids in dextran sulphate sodium-434 
induced experimental acute colitis in rats. Eur J Gastroenterol Hepatol 13: 107-112, 2001. 435 
 436 
4. Barrasa JI, Olmo N, Lizarbe MA, and Turnay J. Bile acids in the colon, from 437 
healthy to cytotoxic molecules. Toxicol In Vitro 27: 964-977, 2013. 438 
 439 
5. Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: 440 
where are we and where should we go? Eur J Gastroenterol Hepatol 17: 137-140, 2005. 441 
 442 
6. Bezzio C, Furfaro F, de Franchis R, Maconi G, Asthana AK, and Ardizzone S. 443 
Ulcerative colitis: current pharmacotherapy and future directions. Expert Opin Pharmacother 444 
15: 1659-1670, 2014. 445 
 446 
7. Dosa PI, Ward T, Castro RE, Rodrigues CM, and Steer CJ. Synthesis and 447 
evaluation of water-soluble prodrugs of ursodeoxycholic acid (UDCA), an anti-apoptotic bile 448 
acid. ChemMedChem 8: 1002-1011, 2013. 449 
 450 
8. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, Thomas 451 
G, Barbu V, Humbert L, Despras G, Bridonneau C, Dumetz F, Grill JP, Masliah J, 452 
Beaugerie L, Cosnes J, Chazouilleres O, Poupon R, Wolf C, Mallet JM, Langella P, 453 
Trugnan G, Sokol H, and Seksik P. Connecting dysbiosis, bile-acid dysmetabolism and gut 454 
inflammation in inflammatory bowel diseases. Gut 62: 531-539, 2013. 455 
 456 
9. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, 457 
Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, and Lindor 458 
KD. High-dose ursodeoxycholic acid is associated with the development of colorectal 459 
neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J 460 
Gastroenterol 106: 1638-1645, 2011. 461 
 462 
10. Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, and Tong Y. Bear bile: 463 
dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed 5: 2, 464 
2009. 465 
11. Furrie E, Macfarlane S, Thomson G, Macfarlane GT, Microbiology, Gut Biology 466 
G, Tayside T, and Tumour B. Toll-like receptors-2, -3 and -4 expression patterns on human 467 
colon and their regulation by mucosal-associated bacteria. Immunology 115: 565-574, 2005. 468 
 469 
12. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, 470 
Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, 471 
Adorini L, Moschetta A, and van Mil SW. Farnesoid X receptor activation inhibits 472 
20 
 
inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60: 463-473 
472, 2011. 474 
 475 
13. Hamilton JP, Xie G, Raufman JP, Hogan S, Griffin TL, Packard CA, Chatfield 476 
DA, Hagey LR, Steinbach JH, and Hofmann AF. Human cecal bile acids: concentration 477 
and spectrum. Am J Physiol Gastrointest Liver Physiol 293: G256-263, 2007. 478 
 479 
14. Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, and 480 
Schoonjans K. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. 481 
Sci Rep 2: 430, 2012. 482 
 483 
15. Hofmann AF. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug 484 
hepatotoxicity. Drug Metab Rev 36: 703-722, 2004. 485 
 486 
16. Kelly OB, Mroz MS, Ward JB, Colliva C, Scharl M, Pellicciari R, Gilmer JF, 487 
Fallon PG, Hofmann AF, Roda A, Murray FE, and Keely SJ. Ursodeoxycholic acid 488 
attenuates colonic epithelial secretory function. J Physiol 591: 2307-2318, 2013. 489 
 490 
17. Knights D, Lassen KG, and Xavier RJ. Advances in inflammatory bowel disease 491 
pathogenesis: linking host genetics and the microbiome. Gut 62: 1505-1510, 2013. 492 
 493 
18. Kozoni V, Tsioulias G, Shiff S, and Rigas B. The effect of lithocholic acid on 494 
proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect 495 
on apoptosis in the presence of a colon carcinogen. Carcinogenesis 21: 999-1005, 2000. 496 
 497 
19. Kumar DP, Asgharpour A, Mirshahi F, Park SH, Liu S, Imai Y, Nadler JL, 498 
Grider JR, Murthy KS, and Sanyal AJ. Activation of Transmembrane Bile Acid Receptor 499 
TGR5 Modulates Pancreatic Islet alpha Cells to Promote Glucose Homeostasis. J Biol Chem 500 
291: 6626-6640, 2016. 501 
 502 
20. Kuo SM, Merhige PM, and Hagey LR. The effect of dietary prebiotics and 503 
probiotics on body weight, large intestine indices, and fecal bile acid profile in wild type and 504 
IL10-/- mice. PLoS One 8: e60270, 2013. 505 
 506 
21. Laukens D, Devisscher L, Van den Bossche L, Hindryckx P, Vandenbroucke RE, 507 
Vandewynckel YP, Cuvelier C, Brinkman BM, Libert C, Vandenabeele P, and De Vos 508 
M. Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal 509 
epithelial cell death. Lab Invest 94: 1419-1430, 2014. 510 
 511 
22. Lee JY, Arai H, Nakamura Y, Fukiya S, Wada M, and Yokota A. Contribution of 512 
the 7beta-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic 513 
acid formation in the human colon. J Lipid Res 54: 3062-3069, 2013. 514 
 515 
23. Li T, and Chiang JY. Bile acids as metabolic regulators. Curr Opin Gastroenterol 516 
31: 159-165, 2015. 517 
 518 
24. Maillette de Buy Wenniger L, and Beuers U. Bile salts and cholestasis. Dig Liver 519 
Dis 42: 409-418, 2010. 520 
 521 
21 
 
25. Martinez-Moya P, Romero-Calvo I, Requena P, Hernandez-Chirlaque C, 522 
Aranda CJ, Gonzalez R, Zarzuelo A, Suarez MD, Martinez-Augustin O, Marin JJ, and 523 
de Medina FS. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in 524 
experimental colitis. Int Immunopharmacol 15: 372-380, 2013. 525 
 526 
26. Merga Y, Campbell BJ, and Rhodes JM. Mucosal barrier, bacteria and 527 
inflammatory bowel disease: possibilities for therapy. Dig Dis 32: 475-483, 2014. 528 
 529 
27. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal 530 
A, Monaco CL, Zhao G, Fleshner P, Stappenbeck TS, McGovern DP, Keshavarzian A, 531 
Mutlu EA, Sauk J, Gevers D, Xavier RJ, Wang D, Parkes M, and Virgin HW. Disease-532 
specific alterations in the enteric virome in inflammatory bowel disease. Cell 160: 447-460, 533 
2015. 534 
 535 
28. Odenwald MA, and Turner JR. Intestinal permeability defects: is it time to treat? 536 
Clin Gastroenterol Hepatol 11: 1075-1083, 2013. 537 
 538 
29. Ooi JH, Li Y, Rogers CJ, and Cantorna MT. Vitamin D regulates the gut 539 
microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr 143: 1679-540 
1686, 2013. 541 
 542 
30. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, and Pizarro TT. Central role of 543 
the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons 544 
learned from animal models and human genetics. Front Immunol 4: 280, 2013. 545 
 546 
31. Perse M, and Cerar A. Dextran sodium sulphate colitis mouse model: traps and 547 
tricks. J Biomed Biotechnol 2012: 718617, 2012. 548 
 549 
32. Roda A, Pellicciari R, Cerre C, Polimeni C, Sadeghpour B, Marinozzi M, Forti 550 
GC, and Sapigni E. New 6-substituted bile acids: physico-chemical and biological 551 
properties of 6 alpha-methyl ursodeoxycholic acid and 6 alpha-methyl-7-epicholic acid. J 552 
Lipid Res 35: 2268-2279, 1994. 553 
 554 
33. Rodrigues CM, Fan G, Wong PY, Kren BT, and Steer CJ. Ursodeoxycholic acid 555 
may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane 556 
potential and reactive oxygen species production. Mol Med 4: 165-178, 1998. 557 
 558 
34. Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, and Sanchez 559 
Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic 560 
applications. Clin Sci (Lond) 121: 523-544, 2011. 561 
 562 
35. Sakanaka T, Inoue T, Yorifuji N, Iguchi M, Fujiwara K, Narabayashi K, 563 
Kakimoto K, Nouda S, Okada T, Kuramoto T, Ishida K, Abe Y, Takeuchi T, Umegaki 564 
E, Akiba Y, Kaunitz JD, and Higuchi K. The effects of a TGR5 agonist and a dipeptidyl 565 
peptidase IV inhibitor on dextran sulfate sodium-induced colitis in mice. J Gastroenterol 566 
Hepatol 30 Suppl 1: 60-65, 2015. 567 
 568 
36. Salim SY, and Soderholm JD. Importance of disrupted intestinal barrier in 569 
inflammatory bowel diseases. Inflamm Bowel Dis 17: 362-381, 2011. 570 
22 
 
37. Sola S, Aranha MM, Steer CJ, and Rodrigues CM. Game and players: 571 
mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr Issues 572 
Mol Biol 9: 123-138, 2007. 573 
 574 
38. Tadano T, Kanoh M, Matsumoto M, Sakamoto K, and Kamano T. Studies of 575 
serum and feces bile acids determination by gas chromatography-mass spectrometry. Rinsho 576 
Byori 54: 103-110, 2006. 577 
 578 
39. Tambuwala MM, Manresa MC, Cummins EP, Aversa V, Coulter IS, and Taylor 579 
CT. Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with 580 
reduced systemic exposure in a murine model of colitis. J Control Release 217: 221-227, 581 
2015. 582 
 583 
40. Terc J, Hansen A, Alston L, and Hirota SA. Pregnane X receptor agonists enhance 584 
intestinal epithelial wound healing and repair of the intestinal barrier following the induction 585 
of experimental colitis. Eur J Pharm Sci 55: 12-19, 2014. 586 
 587 
41. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, 588 
Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, and Schoonjans K. 589 
TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177, 590 
2009. 591 
 592 
42. Torres J, Danese S, and Colombel JF. New therapeutic avenues in ulcerative colitis: 593 
thinking out of the box. Gut 62: 1642-1652, 2013. 594 
 595 
43. Van den Bossche L, Hindryckx P, Devisscher L, Devriese S, Van Welden S, 596 
Holvoet T, Vilchez-Vargas R, Vital M, Pieper DH, Vanden Bussche J, Vanhaecke L, 597 
Van de Wiele T, De Vos M, and Laukens D. Ursodeoxycholic acid and its taurine/glycine 598 
conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in 599 
mice. Appl Environ Microbiol 2017. 600 
 601 
44. van Gorkom BA, van der Meer R, Boersma-van Ek W, Termont DS, de Vries 602 
EG, and Kleibeuker JH. Changes in bile acid composition and effect on cytolytic activity of 603 
fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over 604 
intervention trial in healthy volunteers. Scand J Gastroenterol 37: 965-971, 2002. 605 
 606 
45. Vang S, Longley K, Steer CJ, and Low WC. The Unexpected Uses of Urso- and 607 
Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med 3: 608 
58-69, 2014. 609 
 610 
46. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, 611 
Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, and Auwerx 612 
J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone 613 
activation. Nature 439: 484-489, 2006. 614 
 615 
47. Williamson KD, and Chapman RW. Primary sclerosing cholangitis. Dig Dis 32: 616 
438-445, 2014. 617 
 618 
48. Wirtz S, Neufert C, Weigmann B, and Neurath MF. Chemically induced mouse 619 
models of intestinal inflammation. Nat Protoc 2: 541-546, 2007. 620 
23 
 
COMPETING INTERESTS: The authors have no competing interests to report. 621 
 622 
ACKNOWLEDGEMENTS: This work was supported by a Science Foundation Ireland 623 
Principal Investigator Award (10/IN.1/B2983) and a Crohn’s and Colitis Foundation of 624 
America Senior Investigator Award to SJK. The authors would like to thank Prof. Alan F. 625 
Hofmann (University of California, San Diego) for his helpful discussion during the 626 
preparation of this manuscript.  627 
 628 







